What is the difference between an FDA Section 361 and Section 351 biologic?

Section 361 tissue products are regulated solely under 21 CFR Part 1271 as Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). They require minimal manipulation, homologous use, and no pre-market approval. Section 351 products involve higher risk, non-homologous use, or systemic metabolic activity, requiring FDA drug approval through an IND or BLA application.

Does FDA registration of a tissue bank mean the product is FDA approved?

No. FDA Establishment Registration is an administrative listing requirement for facilities processing or storing HCT/Ps; it does not constitute FDA approval, endorsement, or evaluation of individual tissue products.

What documentation should a clinic request before buying tissue biologics?

A practice should request the vendor's active FDA Establishment Registration (Form 2830), state tissue bank licenses, product-specific Certificates of Analysis (CoA) confirming sterility and donor screening, and detailed handling protocols.

How does homologous use impact medical practice compliance?

Homologous use requires that the tissue biologic perform the same basic repair or structural function in the recipient as it did in the donor. Marketing or using a Section 361 product for a non-homologous purpose reclassifies the tissue as an unapproved Section 351 drug.

FDA Section 361 Compliance Checklist for Tissue Procurement

An FDA Section 361 compliance checklist for clinic procurement of tissue biologics provides practice managers with a standardized protocol to verify tissue establishment registrations, donor eligibility records, and certificates of analysis. By auditing these documentation requirements before order placement, clinics ensure their human cells, tissues, and cellular and tissue-based products (HCT/Ps) meet 21 CFR Part 1271 criteria without risking classification as unapproved biologics. Learn how to structure your procurement workflow to protect practice licensure and streamline inventory management for all biologics.

Navigating FDA Section 361 vs Section 351 HCT/P Regulations

When evaluating human cellular and tissue-based products for clinical service lines, practice administrators and purchasing directors must distinguish between products regulated solely under Section 361 of the Public Health Service (PHS) Act and those classified as Section 351 drugs or biological products. Section 361 tissue products do not require pre-market approval, clinical trial testing, or FDA licensing, provided they meet strict criteria designed to prevent the transmission of communicable diseases.

Under 21 CFR Part 1271.10(a), an HCT/P is regulated under Section 361 if it satisfies four specific requirements:

Minimal Manipulation: Processing does not alter the relevant biological characteristics of structural tissue or the systemic function of non-structural tissue.
Homologous Use: The tissue is intended to perform the same basic function in the recipient as it performed in the donor.
No Unapproved Combination: The product is not combined with another article, such as a drug or device, except for water, crystalloids, or specific sterilizing/preserving agents.
Systemic Effect and Cellular Metabolic Activity: The product either does not have a systemic effect and is not dependent on the metabolic activity of living cells, or it is intended for autologous use, allogeneic use in first- or second-degree relatives, or reproductive use.

If a biologic product fails any single criterion of this test—such as claiming a non-homologous systemic indication or undergoing extensive enzymatic processing—it is classified as a Section 351 drug. Procuring a Section 351 product that lacks an approved Investigational New Drug (IND) application or Biologics License Application (BLA) exposes the clinical practice to severe compliance actions, regulatory warnings, and potential medical board review.

FDA Section 361 Compliance Checklist for Clinic Procurement

To establish a compliant workflow for procuring tissue biologics, clinical managers should execute the following verification steps prior to issuing a purchase order:

1. Vendor & Tissue Bank Registration

[ ] Confirm the tissue processor holds an active FDA Tissue Establishment Registration via the FDA eLIST database.
[ ] Obtain a current copy of the vendor's FDA Form 2830 (Blood Establishment Registration and Product Listing).
[ ] Verify state-level tissue bank licensing if applicable to your practice location.

2. Product Qualification Criteria

[ ] Review donor screening and testing protocols to ensure adherence to 21 CFR Part 1271 Subpart C (testing for HIV, Hepatitis B/C, Syphilis, HTLV, and relevant communicable disease agents).
[ ] Verify that product labeling explicitly outlines homologous use indications matching clinical intent.
[ ] Confirm the manufacturer's processing methodology meets minimal manipulation definitions (e.g., mechanical micronization vs. chemical alteration).
[ ] Ensure no added active pharmaceutical ingredients (APIs), unapproved growth factors, or synthetic carriers are included.

3. Supply Chain & Storage Documentation

[ ] Confirm receipt of batch-specific Certificates of Analysis (CoA) for every incoming lot.
[ ] Review validated cold chain transport protocols (dry ice, liquid nitrogen vapor, or controlled ambient shippers).
[ ] Establish internal temperature logging procedures for ambient or cryopreserved inventory storage.
[ ] Verify product traceability protocols, ensuring the clinic can link donor lot numbers to specific patient medical records.

Operational vs. Clinical Sourcing Considerations

Successful biologic procurement requires alignment between the clinical team performing procedures and the operational team managing practice finances and risk.

Clinical Sourcing Requirements

For clinicians, particularly those specializing in pain management or sports medicine, the primary focus is handling characteristics, tissue viability, structural integrity, and clinical safety profiles. Physicians must verify that donor screening protocols meet rigorous standards and that the product handling instructions (such as thaw times, rehydration protocols, and needle gauge compatibility) integrate smoothly into procedural workflows.

Operational and Procurement Requirements

For practice managers, procurement centers on risk mitigation, unit cost structure, storage requirements, and audit readiness. Administrators must balance storage logistics—such as maintaining ultra-low temperature freezers versus room-temperature shelf-stable allografts—against procedural demand. Operational leaders must also enforce strict lot-tracking protocols in the practice Electronic Health Record (EHR) system to maintain compliance during state board or FDA facility audits.

Common Red Flags in Biologic Vendor Procurement

Practice managers should exercise extreme caution and halt procurement if a supplier exhibits any of the following warning signs:

Disease Cure Claims: Vendors claiming that a Section 361 tissue biologic treats systemic diseases, neurological conditions, or organ failure. Section 361 products cannot claim systemic therapeutic mechanisms.
Lack of Lot-Specific CoAs: Inability or refusal to provide donor screening records, sterility testing results, and Certificates of Analysis for every shipped lot.
Opaque Processing Protocols: Refusal to clarify whether tissue processing involves enzymatic digestion, cellular expansion, or chemical modification.
Unregistered Facilities: Foreign or domestic suppliers relying on third-party marketing entities without direct links to an FDA-registered tissue processor.

What This Means for Your Practice: Concrete Next Steps

To safeguard your practice infrastructure and maintain clinical excellence, take immediate operational steps to standardize your procurement model:

Conduct an Internal Biologics Audit: Audit all tissue allografts, amniotic membranes, and cellular products currently in your inventory against FDA registration records and 21 CFR Part 1271 guidelines.
Update Standard Operating Procedures (SOPs): Establish formal written SOPs for tissue receipt, logging, lot-to-patient tracking, and temperature verification upon arrival.
Implement Vendor Qualification Protocols: Require all prospective biologic distributors and manufacturers to complete a formal vendor compliance packet before issuing purchase orders.
Educate Clinical and Administrative Staff: Ensure both procedural staff and procurement personnel understand the regulatory boundaries between Section 361 tissue products and Section 351 drugs.

To learn more about compliant tissue sourcing and vendor qualification, explore our about us page or browse our clinical FAQ section.

For customized guidance on standardizing compliant biologic procurement for your practice, contact Dallas Regenerative Solutions to schedule an operational consultation.